Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Monopar Therapeutics Inc.NASDAQ: MNPR
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 9.6% from a year ago
Common stock stood at $6.7K at the end of Q1 FY2026, up 9.6% from a year earlier and up 0.1% from the prior quarter. Over 3 fiscal years it compounded at -19.7% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +9.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 6.69K USD
- Year-over-year change
- +9.7%
- 4-year CAGR
- -14.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.69K | +9.7% |
| FY2024 | 2024-12-31 | 6.1K | -59.1% |
| FY2023 | 2023-12-31 | 14.91K | +15.1% |
| FY2022 | 2022-12-31 | 12.95K | +2.8% |
| FY2021 | 2021-12-31 | 12.6K | — |
Common Stock vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +9.6% is the 6th highest of 11, against a peer median of +8.0%.
- Common stock amounts to 0.0% of total assets for MNPR, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.15B USD | +4.2% | +7.1% | 97.5% | |
| Mar 2026 | $11.23M USD | +33.0% | +14.9% | 3.9% | |
| Dec 2025 | €4.69M EUR | +11.8% | +5.3% | 7.5% | |
| Mar 2026 | $899K USD | +0.8% | +32.2% | 0.1% | |
| Jun 2026 | $744K USD | +4.2% | +6.1% | 0.1% | |
| Mar 2026 | $636K USD | +0.8% | +0.9% | 0.3% | |
| Mar 2026 | $135K USD | +154.7% | +9.6% | 0.1% | |
| Jun 2026 | $31K USD | +0.0% | +6.0% | 0.1% | |
| Mar 2026 | $18K USD | +28.6% | +11.5% | 0.0% | |
| Sep 2026 | $11K USD | +22.2% | +122.4% | 0.0% | |
| Mar 2026 | $6.7K USD | +9.6% | -19.7% | 0.0% | |
| Peer median (excluding MNPR) | — | +8.0% | +8.3% | 0.1% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.